Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Stange, S. Mitzner, W. Ramlow, et al.
Dyalisis against an on line recycled albumin circle enables removal of proteins bound toxins.
Artif Organs, 17 (1993), pp. 809-813
[2.]
J. Stange, S. Mitzner, W. Ramlow, et al.
A new procedure for the removal protein bound drugs and toxins.
ASAIO J, 39 (1993), pp. M621-M625
[3.]
J. Stange, W. Ramlow, S. Mitzner, et al.
Dialysis against a recycled albumin solution enables the removal of albumin bound toxins.
Artif Organs, 17 (1993), pp. 809-813
[4.]
Mitzner S. Liver dialysis. MARS (Molecular Absorbent Recirculating System). A new blood. Del manual de procedimientos dialíticos para MARS. S/año Detoxification Method.
[5.]
S.R. Mitzner, J. Stange, S. Klammt, et al.
Albumin dialysis using the molecular absorbent recirculating system.
Nephrology and Hypertension, 10 (2001), pp. 777-783
[6.]
D. Kapoor.
Molecular absorbent recirculating system: albumin dialysis-based extracorporeal liver assist device.
J Gastroenterol Hepatol, 17 (2002), pp. S280-S286
[7.]
J. Stange, S.R. Mitzner, W. Ramlow, et al.
Mass transfer of albumin bound toxins through membranes-comparision between hemofiltration and the MARS system.
ASAIO J, 41 (1995), pp. 11
[8.]
J. Stange, S.R. Mitzner, T. Risler, et al.
Moleculas absorbent recirculating system (MARS): clinical results of a new membrane – based blood purification system for bioartificial liver support.
Artif Organs, 23 (1997), pp. 319-330
[9.]
T. Peters.
All about albumin: biochemistry, genetics and medical applications.
Academic Press Inc, (1996),
[10.]
Teraklin. Del manual de operación teórico práctico. Sistema MARS® ref: 800010, 800118, 800311, 800326. S/año
[11.]
W.C. Maddrey, J.K. Boitnott, M.S. Bedine, et al.
Corticosteroid therapy of alcoholic hepatitis.
Gastroenterology, 75 (1978), pp. 193-199
[12.]
Teraklin. Del manual de: Indications for MARS® therapy. S/año.
[13.]
Steiner Ch, Viertler A, Zinggrebe A. International MARS Registry
[14.]
L.L. Kjaergard, Liu Jianping, B. als-Nielsen, et al.
Artificial and bioartificial support systems for acute and acute-on-chronic liver failure.
JAMA, 289 (2003), pp. 217-221
[15.]
S.R. Mitzner, J. Stange, S. Klammt, et al.
Improvement of hepatorenal syndrome with extracorporeal albumin dyalisis MARS: results of a prospective, randomized, controlled clinical trial.
Liver Transpl, 6 (2000), pp. 277-286
[16.]
S.R. Mitzner, S. Klammt, P. Peszynski, et al.
Improvement of multiorgan functions in hepatorenal syndrome during albumin dyalisis with the molecular adsorbent recirculating system.
Ther Apher, 5 (2001), pp. 417-422
[17.]
J. Stange, T.I. Hassanein, R. Mehta, et al.
The molecular adsorbent recycling system as a liver support system based on albumin dyalisis: a summary of preclinical investigations, prospective, randomized controlled trials, and clinical experience from 19 centers.
Artif Organs, 26 (2002), pp. 103-110
[18.]
L.E. Schmidt, V. Romming, L. Bo, et al.
Hemodynamic changes during a single treatment with molecular absorbent recirculating system in patients with acute on chronic liver failure.
Liver Transpl, 7 (2001), pp. 1034-1039
[19.]
A. Parés, A. Escorsell, L. Cisneros, et al.
Improvement in systemic hemodynamics after albumin dialysis is associated with decrease in vasoactive agents [abstract].
Hepatol, 38 (2003), pp. 6
[20.]
R. Jalan, R. Williams.
Acute-on-chronic liver failutre: pathophysiological basis of therapeutic options.
Blood Purif, 20 (2002), pp. 252-261
[21.]
R.B. Abraham, O. Szold, H. Merhav, et al.
Rapid resolution of brain edema and improvement cerebral perfusion pressure following the molecular absorbent recirculating system in acute liver failure patients.
Transplant Proc, 33 (2001), pp. 2897-2899
[22.]
L.E. Schmidt, L.B. Svendsen, V.R. Sorensen, et al.
Cerebral blow flow velocity increases during a single treatment with molecular adsorbents recirculating system in patients with acute on chronic liver failure.
LiverTranspl, 7 (2001), pp. 709-712
[23.]
R. Jalan, R. Williams.
Improvement in cerebral perfusion after MARS therapy: further clues about the pathogenesis of hepatic encephalopathy?.
Liver Transpl, 7 (2001), pp. 713-715
[24.]
R. Jalan, S. Sen, Ch. Steiner, et al.
Extracorporeal liver support with molecular absorbents recirculating system in patients with severe acute alcoholic hepatitis.
J Hepatol, 38 (2003), pp. 24-31
[25.]
A. Parés, R. Deulofeu, L. Cisneros, et al.
Albumin dialysis decreases aromatic amino acids and improves hepatic encephalopathy in patients with severe liver dysfunction [abstract].
J Hepatol, 38 (2003), pp. 6
[26.]
U. Heemann, U. Treichel, J. Loock, et al.
Albumin dialysis in cirrhosis with superimposed acute liver injury; a prospective controlled study.
Hepatology, 36 (2002), pp. 949-958
[27.]
M. Seige, B. Kreymann, B. Jeschke, et al.
Long term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis.
Transpl Proc, 31 (1999), pp. 1371-1375
[28.]
M. Macía, J. Aviles, J. Navarro, et al.
Efficacy of the molecular absorbent recirculating system for the treatment of intractable pruritus in cholestais.
Am J Med, 11 (2003), pp. 375-379
[29.]
A. Parés, L. Cisneros, J. Salmerón, et al.
Molecular Adsorbent Recirculating System: a new procedure for relieving intractable pruritus in patients with primary biliary cirrhosis [en prensa].
Am J Gastroenterol, (2004),
[30.]
X. Badia, M. Salamero, J. Alonso.
La medida de la salud. Guía de escalas de medición en español.
2.a ed., Edimac, (1999),
[31.]
F.H.J. Wolfhagen, E. Sternieri, W.C.J. Hop, et al.
Oral naltrexone treatment for cholestasic pruritus: a double blind, placebo-controlled study.
Gastroenterology, 113 (1997), pp. 1264-1269
[32.]
R.N. Pugh, I.M. Murray-Lyon, J.L. Dawson, et al.
Transection of the oesophagus for bleeding oesophageal varices.
Br J Surg, 60 (1973), pp. 649
[33.]
H.O. Conn, C.M. Leevy, Vlahcevic, et al.
Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalophaty. A double blind controlled trial.
Gastroenterology, 72 (1977), pp. 573-583
[34.]
M. Groeneweg, W. Moerland, J.C. Quero, et al.
Screening of subclinical hepatic encephalopathy.
J Hepatol, 32 (2000), pp. 748-753
[35.]
R.M. Reitan.
Validity of the trail making test as an indication of organic brain damage.
Percep Mot Skills, 8 (1958), pp. 271-276
[36.]
R.A. De Melker, F. Touw-Otten, H.M. Jacobs, et al.
De waarde van de Sickness Impact Profile.
Ned Tijdschr Geneeskd, 134 (1990), pp. 946-948
[37.]
U. Johansson, T. Andersson, A. Persson, et al.
Visual evoked potential – a tool in the diagnosis of hepatic encephalopathy?.
J Hepatol, 2 (1998), pp. 227-233
Copyright © 2005. Elsevier España S.L.. Todos los derechos reservados
